Krystal Biotech, Inc. balance sheet KRYS

Annual Quarterly

As of Sep 30, 2026, Krystal Biotech, Inc. had total assets of $1.6 billion and total liabilities of $150.5 million. Total assets were up 27.9% from a year earlier. Stockholders' equity was $1.4 billion. It held $1.2 billion in cash and investments against $8.6 million of total debt, net cash of $1.2 billion. The current ratio, current assets divided by current liabilities, was 7.89.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2021 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2017 Dec 31, 2017
Assets
Cash	463 +17.9%	496 +43.9%	345 -3.8%	358	162 -39.7%	341 +27.2%	268 +43.1%	188	50
Short-term investments	449 +32.7%	331 +31.2%	253 +45.3%	174	217 +7159.3%	97 +3135.9%	3 -51.5%	6	—
Long-term investments	282 +112.1%	128 -15.8%	152 +145.5%	62	5	64	0 -100.0%	0	—
Cash and investments	1,194 +38.2%	956 +27.5%	750 +26.2%	594	384 +41.5%	502 +85.2%	271 +39.7%	194	50
Receivables	133 +2.7%	127 +21.7%	105 +149.2%	42	—	—	—	—	—
Inventory	51 +35.0%	40 +52.7%	27 +279.5%	7	—	—	—	—	—
Total current assets	1,122 +21.2%	1,025 +38.1%	742 +26.2%	588	384 +39.5%	442 +60.8%	275 +40.4%	196	50
Property and equipment, net	152 +2.3%	151 -2.8%	155 -3.7%	161	162 +423.7%	112 +263.9%	31 +264.3%	8	0
Total assets	1,586 +27.9%	1,334 +26.3%	1,056 +29.0%	818	558 +79.7%	626 +101.5%	311 +48.7%	209	50
Liabilities and equity
Accounts payable	7 +221.0%	3 -35.0%	5 +20.6%	4	4 +89.1%	8 +299.0%	2 +106.2%	1	0
Total current liabilities	142 +55.7%	103 +0.9%	102 +208.2%	33	29 +86.7%	26 +66.6%	15 +364.4%	3	1
Total liabilities	150 +47.2%	114 +4.4%	109 +175.6%	40	36 +93.1%	33 +74.4%	19 +207.1%	6	1
Stockholders' equity	1,436 +26.2%	1,220 +28.9%	946 +21.5%	779	522 +78.8%	594 +103.2%	292 +43.9%	203	49
Debt
Lease liabilities	9 -9.7%	9 +28.6%	7 -10.3%	8	9 -35.9%	8 -42.5%	4 -14.4%	5	—
Total debt	9 -9.7%	9 +28.6%	7 -10.3%	8	9 -35.9%	8 -42.5%	4 -14.4%	5	—
Net cash	1,186 +38.7%	947 +27.5%	742 +26.7%	586	375 +45.7%	494 +92.2%	267 +41.0%	190	—
Ratios
Current ratio	7.89x	9.95x	7.28x	17.76x	13.30x	17.18x	17.80x	58.88x	77.99x
Debt to equity	0.01x	0.01x	0.01x	0.01x	0.02x	0.01x	0.01x	0.02x	—
Debt to EBITDA	0.04x	0.06x	0.10x	—	—	—	—	—	—
Return on equity	15.68%	16.80%	9.42%	1.40%	-26.80%	-23.58%	-11.01%	-9.41%	-16.01%
Return on assets	14.20%	15.36%	8.44%	1.34%	-25.06%	-22.35%	-10.35%	-9.13%	-15.80%
Book value per share	48.45	41.78	32.87	27.58	20.27	23.55	14.82	11.69	4.80

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: KRYS (Nasdaq)
Fiscal year ends: December 31
Headquarters: Pittsburgh, PA
SEC filer status: Large accelerated filer
SEC CIK: 1711279

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.